BBS

Rhythm Pharmaceuticals and Genpharm Announce Collaboration to Provide IMCIVREE® (setmelanotide) to Patients in Gulf Cooperation Council Countries

Retrieved on: 
Monday, May 22, 2023
Polyphagia, LEPR, Obesity, International, Prevalence, GCC, Bardet–Biedl syndrome, POMC, BBS, Patient, PCSK1, European, United Kingdom, MC4R, Gulf Cooperation Council, Rare, Heads of International Research Organizations, Pharmaceutical industry

Under the terms of this exclusive agreement, Genpharm will distribute IMCIVREE to patients in GCC countries for the treatment of hyperphagia and obesity due to Bardet-Biedl syndrome (BBS) or genetically-confirmed biallelic pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency.

Key Points: 
  • Under the terms of this exclusive agreement, Genpharm will distribute IMCIVREE to patients in GCC countries for the treatment of hyperphagia and obesity due to Bardet-Biedl syndrome (BBS) or genetically-confirmed biallelic pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency.
  • IMCIVREE is approved for these indications in the United States, Canada, the United Kingdom and the European Union.
  • Providers in the region now have the ability to prescribe IMCIVREE to qualifying patients who they believe will benefit from the therapy.
  • “Due to many factors, GCC countries have an increased prevalence of certain genetic diseases, creating a significant demand for precision therapies, like IMCIVREE, that address illnesses at their root cause,” said Kamel Ghammachi, Genpharm Chairman.

Supply Chain Innovation Technology Company Trendsi Appoints Head of North America Logistics

Retrieved on: 
Tuesday, May 16, 2023
Overload, Pressure, Perseverance, Software as a service, Travel, L'Oréal, Life, Big data, Internet, Head, Shanghai Jiao Tong University, Clothing, Intelligence, Shopify, Android, University of the Philippines Los Baños College of Economics and Management, Shanghai Waigaoqiao Free Trade Zone, IOS, Hoarding, BBS, Silicon, Running, Entrepreneurship, Data analysis, Dream, Data as a service, VMI, Immersion, ISBN, Tsinghua University, Paper, Growth, Knowledge, Economic Hardship Reporting Project, Yoy, Family, RMB, Automation, Film industry, Creative industries, Warehouse, Online shopping, Retail, Management, Book, Video game, Chinese, Economics

SHANGHAI, May 15, 2023 /PRNewswire/ -- U.S. supply chain innovation technology company Trendsi announces the appointment of Zhi Zhang as Head of North America Logistics.

Key Points: 
  • SHANGHAI, May 15, 2023 /PRNewswire/ -- U.S. supply chain innovation technology company Trendsi announces the appointment of Zhi Zhang as Head of North America Logistics.
  • Now, with Trendsi, Zhang is applying data intelligence to build a flexible supply chain and logistics infrastructure and is dedicated to filling the gaps in manufacturing automation.
  • Zhang is impressed by China's advanced flexible supply chain and well-established e-com fulfillment logistics infrastructure, which is already in place.
  • However, Zhang's expertise lies in his innovative use of logistics data analysis, which has enabled intelligent logistics operations for the entire supply chain, resulting in a more flexible, proactive, and efficient logistics system for Trendsi.

Dr. George Lam Officially Joins VSFG as Honorary Chairman

Retrieved on: 
Tuesday, May 16, 2023
Sustainability, Pacific Basin Economic Council, Sustainable Business Network, Central Policy Unit, Multilateralism, Financial services, SFC, Policy, Youth Development Commission, HKSAR Government, CPA Australia, High court, Sir Murray Pringle, 10th Baronet, Government, Committee, BBS, Entrepreneurship, United Nations Economic and Social Commission for Asia and the Pacific, Investment, Securities and Futures Commission, UN, ESBN, United Nations Economic and Social Council, Growth, ESG, Belt, Commerce, Property management, Cyberport, HKSAR

HONG KONG, May 16, 2023 - (ACN Newswire) - To drive the strategic development of innovative financial services, Venture Smart Financial Holdings Limited (hereinafter referred to as "VSFG" or "the Group") officially announced the appointment of Dr. George Lam, BBS, JP ("Dr. Lam") as Honorary Chairman today.

Key Points: 
  • HONG KONG, May 16, 2023 - (ACN Newswire) - To drive the strategic development of innovative financial services, Venture Smart Financial Holdings Limited (hereinafter referred to as "VSFG" or "the Group") officially announced the appointment of Dr. George Lam, BBS, JP ("Dr. Lam") as Honorary Chairman today.
  • Dr. Lam said, "I have accepted the invitation from Mr. Lawrence Chu, Chairman of VSFG, because we share the same vision for the future development of Hong Kong's financial industry.
  • VSFG is the first virtual asset manager in Hong Kong licensed by the Hong Kong Securities and Futures Commission ("SFC").
  • Mr. Lawrence Chu, Chairman of VSFG, also expressed his sincere appreciation to Dr. Lam for joining and supporting VSFG, "As a farsighted visionary, Dr. Lam has always been driving the integration of the new and traditional economies without neglecting the importance of regulations and corporate governance.

Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® Setmelanotide Injection for Weight Management in Bardet-Biedl Syndrome or Genetically-confirmed Biallelic POMC, PCSK1, or LEPR Deficiency

Retrieved on: 
Monday, May 8, 2023
LEPR, Hospital for Sick Children, Faculty, University of Alberta, Benzyl alcohol, Priority review, Obesity, Depression, University, Weight loss, Bardet–Biedl syndrome, Pigment, POMC, BBS, Very early onset inflammatory bowel disease, Arousal, Publication, Patient, PCSK1, The Hospital, Medicine, Hypothalamus, Nausea, Suicidal ideation, University of Melbourne Faculty of Medicine, Dentistry and Health Sciences, Health Canada, Hunger, Human, Skin, Pharmaceutical industry, Nursing, Endocrinology, MC4R

BOSTON, May 08, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company, today announced that Health Canada has approved IMCIVREE® (setmelanotide solution for subcutaneous injection) for weight management in adult and pediatric patients 6 years of age and older with obesity due to Bardet-Biedl syndrome (BBS) or genetically-confirmed biallelic pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency due to variants interpreted as pathogenic, likely pathogenic, or of uncertain significance. Please consult the IMCIVREE product monograph available at www.rhythmtx.ca.

Key Points: 
  • Setmelanotide has been shown to reduce the weight of patients living with BBS or POMC, PCSK1 or LEPR deficiency.
  • The trials met all primary endpoints and key secondary endpoints among patients at 52 weeks on therapy.
  • Results from these trials were featured in several publications, including the peer-reviewed journal The Lancet Diabetes and Endocrinology .
  • The most common adverse reactions were skin hyperpigmentation, injection site reactions and nausea.

Rhythm Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Update

Retrieved on: 
Tuesday, May 2, 2023
LEPR, Polyphagia, Obesity, Food, International, Completeness, Body mass index, Bardet–Biedl syndrome, Food and Drug Administration, Clinical trial, Prescription, G&A, Advances in Therapy, Research, Ratio, POMC, BBS, CHI, Data analysis, Phase 3, Patient, Investment, Physician, PCSK1, National Association of Statutory Health Insurance Physicians, Webcast, MC4R, Ageing, R, BMI, FDA, Hunger, Acquisition, Human, Congenital hyperinsulinism, D, Pharmaceutical industry, Cryptocurrency, Rhythm, S

-- Management to host conference call today at 8:00 a.m. ET --

Key Points: 
  • ET --
    BOSTON, May 02, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today reported financial results and provided a business update for the first quarter ended March 31, 2023.
  • R&D Expenses: R&D expenses were $37.9 million in the first quarter of 2023, as compared to $32.5 million in the first quarter of 2022.
  • S,G&A Expenses: S,G&A expenses were $24.6 million for the first quarter of 2023, as compared to $21.4 million for the first quarter of 2022.
  • ET today to review its first quarter 2023 financial results and recent business activities.

Broad Arrow and Hagerty Marketplace Launch Retro Motors Collection - Now Available for Online Bidding

Retrieved on: 
Thursday, April 27, 2023
Wagon, Corvette, Collection, Vortech, Life, Mercedes-Benz SLS AMG, GT, Shelby Series 1, Ferrari, Carrozzeria Scaglietti, Metallic, Ford, V8, Scuderia Ferrari, AMG, Roadster, History, Carbon, Sale, BBS, Entire, Burning Desire (song), F1, Chevrolet, Pointe technique, Challenge, Growth, MagneRide, Ferrari F430, NYSE, Nero, Blue, Motorcycle, Auction, Electric motor, Car rental, Daytona

The Retro Motors Collection launches today on Hagerty Marketplace with online auctions presented in a rolling format, with a handful of cars opening for bidding daily.

Key Points: 
  • The Retro Motors Collection launches today on Hagerty Marketplace with online auctions presented in a rolling format, with a handful of cars opening for bidding daily.
  • Offered by a lifelong, passionate enthusiast who has been buying and selling collector cars for decades, each car from The Retro Motors Collection has been inspected and cataloged by a Hagerty Marketplace specialist.
  • Barney Ruprecht, Vice President of Auctions, Hagerty Marketplace, comments: “The Retro Motors Collection is offered by a passionate enthusiast and friend of Hagerty and Broad Arrow who has been collecting his entire adult life.
  • More information on how to register to bid and sell on Hagerty Marketplace online auctions can be found at the website: Hagerty Marketplace .

Hagerty Marketplace Brings Retro Motors Collection to Online Auction Platform

Retrieved on: 
Wednesday, April 26, 2023
Wagon, Corvette, Collection, Vortech, Life, Mercedes-Benz SLS AMG, GT, Shelby Series 1, Ferrari, Carrozzeria Scaglietti, Metallic, Ford, V8, Scuderia Ferrari, AMG, Roadster, History, Carbon, Sale, BBS, Burning Desire (song), F1, Chevrolet, Challenge, Growth, MagneRide, Ferrari F430, NYSE, Nero, Blue, Motorcycle, Auction, Electric motor, Car rental, Daytona

TRAVERSE CITY, Mich., April 26, 2023 /PRNewswire/ -- Hagerty, Inc., (NYSE: HGTY) an automotive lifestyle brand and a leading specialty insurance provider, today announced the offering of Hagerty Marketplace online auction's first private collection sale. The recently launched platform allows members and enthusiasts to buy and sell automobiles through a trusted, easy-to-use system. The Retro Motors Collection comprises over 30 cars largely from the 1950s through today, with a focus on American muscle and high-powered European sports cars. 

Key Points: 
  • The Retro Motors Collection will launch on Hagerty Marketplace online auctions beginning Monday, May 15 in a rolling format, with a handful of cars opening for bidding daily and closing five days following each launch.
  • Offered by a lifelong, passionate enthusiast who has been buying and selling collector cars for decades, each car from The Retro Motors Collection has been inspected and cataloged by a Hagerty Marketplace specialist.
  • Barney Ruprecht, Vice President of Auctions, Hagerty Marketplace, comments: "The Retro Motors Collection is offered by a passionate enthusiast and friend of Hagerty and Broad Arrow who has been collecting his entire adult life.
  • More information on how to register to bid and sell on Hagerty Marketplace online auctions can be found at the website: Hagerty Marketplace .

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Germany for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

Retrieved on: 
Monday, April 24, 2023
Polyphagia, LEPR, Obesity, International, Prevalence, Life, Food and Drug Administration, Bardet–Biedl syndrome, Rhythm, Deficit spending, Polydactyly, Visual impairment, DSM-IV codes, POMC, BBS, Very early onset inflammatory bowel disease, Patient, PCSK1, National Association of Statutory Health Insurance Physicians, Medicine, European, Endocrinology, MC4R, FDA, EC, Hunger, Hypogonadism, Food, European Commission, Pharmaceutical industry, EU

The German Federal Joint Committee (G-BA) ruled that IMCIVREE is eligible for reimbursement by Statutory Health Insurances for BBS.

Key Points: 
  • The German Federal Joint Committee (G-BA) ruled that IMCIVREE is eligible for reimbursement by Statutory Health Insurances for BBS.
  • People living with BBS may experience insatiable hunger, also known as hyperphagia, and severe obesity beginning early in life.
  • In 2022, Rhythm was granted marketing authorization for IMCIVREE by the EC for BBS and early-access authorization for setmelanotide in France.
  • Rhythm expects to launch IMCIVREE for the treatment of patients with BBS in the Netherlands later this year and in Italy, Spain, and the UK in 2024.

HKSTP and AstraZeneca signing MOU on Strategic Collaboration

Retrieved on: 
Tuesday, April 4, 2023
Research, Professional Services, Pharmaceutical, Robotics, Fintech, Technology, Health Technology, Science, Biotechnology, Other Technology, Other Science, Health, Partnership, International, Drug development, Life, JP, SAR, HKSAR, University, Clinical trial, Foot, Multimedia, Innovation, Technology and Industry Bureau, AstraZeneca, Government, BBS, Hong Kong Science and Technology Parks Corporation, I&T, Hospital, Laboratory, Translational research, MOU, Economic development, HKSTP, Guangdong–Hong Kong–Macao Greater Bay Area, Growth, Ecosystem, Policy, Technopolis, Tutoring, Management, Pharmaceutical industry, Innovation

Hong Kong Science and Technology Parks (HKSTP) continues to strengthen the strategic partnership with AstraZeneca, one of the world's leading pharmaceutical companies.

Key Points: 
  • Hong Kong Science and Technology Parks (HKSTP) continues to strengthen the strategic partnership with AstraZeneca, one of the world's leading pharmaceutical companies.
  • Since 2021, AstraZeneca and HKSTP have been collaborating, and this partnership will not only continue but also be upgraded.
  • The extended collaboration involves AstraZeneca and HKSTP supporting and providing services to startup companies under the HKSTP co-incubation programme.
  • Dr Sunny Chai, Chairman of HKSTP, expressed his delight in witnessing the collaboration between HKSTP and AstraZeneca in building a healthcare innovation ecosystem in Hong Kong.

Rhythm Pharmaceuticals Announces Publication of Bardet-Biedl Syndrome Patient and Caregiver Perspectives of Hunger and Quality of Life with Setmelanotide

Retrieved on: 
Monday, March 27, 2023
Polyphagia, Faculty, University of Alberta, Obesity, Food, University, Use, Phase II, Stroke, Weight loss, Bardet–Biedl syndrome, Eating, Quality of life, Advances in Therapy, Research, BBS, Patient, Child, MC4R, University of Melbourne Faculty of Medicine, Dentistry and Health Sciences, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Caregiver, Medicine, Pharmaceutical industry, Residential care, Rhythm, Syndrome, Hunger

BOSTON, March 27, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced the publication of interview-based patient and caregiver reported experiences of hunger and quality of life with setmelanotide treatment in Bardet-Biedl syndrome (BBS). The research is published in the peer-reviewed journal Advances in Therapy.

Key Points: 
  • A total of 19 interviews were conducted with patients (n=8) and caregivers (n=11) to explore patient experience and caregiver observations of hyperphagia before and during setmelanotide treatment.
  • Before setmelanotide treatment, most patients (n=7; 87.5%) and caregivers (n=10; 90.9%) experienced negative effects directly related to hyperphagia.
  • “Until now, the impact of hyperphagia on the lives of these patients and their families has not been fully understood.
  • These data can be incorporated into cost-utility models conducted to assess the value of treatments for rare MC4R pathway diseases.